title: Osteomalacia and secondary hyperparathyroidism after kidney transplantation: Relationship to vitamin D deficiency.
abstract: Secondary hyperparathyroidism is highly prevalent in patients with end-stage renal disease. After successful kidney transplantation, however, parathyroid glands gradually involute to normal size with subsequent normalization of intact parathyroid hormone (PTH), serum calcium, and phosphorous concentrations. This report describes a 48-year-old diabetic end-stage renal disease patient who underwent a successful cadaveric kidney transplant. Serum calcium and phosphorous concentrations normalized within 6 months. Three years later, he presented with complaints of proximal muscle weakness that was progressively worsening. Physical examination revealed temporal wasting and proximal muscle weakness. Detailed neurologic examination was unremarkable except for decreased vibratory sensation in both feet. Laboratory data showed stable allograft function (serum creatinine, 1.3 mg/dL), hypocalcemia, and hypophosphatemia with markedly elevated alkaline phosphatase level (726 IU/L) and intact PTH level (947 pg/mL). Further laboratory evaluation revealed poor nutritional status and severe deficiency of 25(OH)D (4.0 ng/mL). Past medical history included remote episodes of acute pancreatitis due to prior alcohol abuse. Computed tomography of the abdomen showed calcific atrophic pancreas, and steatorrhea was confirmed on stool studies. Decreased bone mineral density was noted by computed tomography bone density scan. Secondary hyperparathyroidism and osteomalacia had developed due to severe vitamin D deficiency, occurring as a result of previously unrecognized, minimally symptomatic pancreatic exocrine insufficiency. Treatment with vitamin D, calcium, and pancreatic enzyme replacement led to remarkable resolution of clinical symptoms and secondary hyperparathyroidism (intact PTH, 65 pg/mL after therapy) and resulted in significant improvement in bone mineralization. Factors associated with vitamin D deficiency in the chronic kidney disease and post-transplant patient population are reviewed.
authors.affiliation: Department of Internal Medicine, University of Tennessee, Memphis, Tennessee, USA.
authors.forename: Hassan
authors.initials: H
authors.lastname: Amin
authors.forename: Barry M
authors.initials: BM
authors.lastname: Wall
authors.forename: C Robert
authors.initials: CR
authors.lastname: Cooke
mesh_terms: D034841:Abdominal Cavity / Q000000981:diagnostic imaging; D000328:Adult; D002118:Calcium / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D016030:Kidney Transplantation; D008297:Male; D010018:Osteomalacia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D010179:Pancreas / Q000000981:diagnostic imaging; D011859:Radiography; D015898:Tomography Scanners, X-Ray Computed; D016896:Treatment Outcome; D014807:Vitamin D / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D014807:Vitamin D; D002118:Calcium